ClinicalTrials.gg
CompletedNCT03425539MODIFYUpdated Aug 9, 2024Results posted

Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease

A Phase 3 interventional study of Lucerastat and Placebo in Fabry Disease, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 49 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing migalastat in Fabry Disease — 2 open to participants now, 3 under way, 3 of them phase 3. migalastat · Fabry Disease.

Enrollment
Largest of 20
118 · median 20
Started
2018
with 2 others
Phase 3
11 of 20
2 open now
Registered
14th of 20
by date
Lead sponsor
3 of 20
Idorsia Pharmaceuticals Ltd.

Among the 20 studies testing migalastat in Fabry Disease, this one has the largest enrollment, is one of 3 that started in 2018, is one of 11 in phase 3, and was the 14th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

2 of the 20 studies testing migalastat in Fabry Disease are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About migalastat

migalastat: first FDA approval 2018 (GALAFOLD), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing migalastat in Fabry Disease, or all of them as a file.
02

Study summary

This study aimed to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease.

Read the detailed description

The primary objective of this prospective, multicenter, double-blind, randomized, placebo-controlled, parallel group, Phase 3 study is to determine the effect of oral lucerastat monotherapy on neuropathic pain in subjects with Fabry disease (FD) through daily collection of patient-reported outcomes with an electronic diary.

03

Conditions studied

  • Fabry Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated ICF prior to any study-mandated procedure;
  2. Male or female adult subjects;
  3. FD diagnosis confirmed with local genetic test results;
  4. Fabry-associated neuropathic pain, as defined by the subject, in the last 3 months prior to screening;
  5. Enzyme replacement therapy (ERT) status:

    1. Subject never treated with ERT; or
    2. Subject has not received ERT for at least 6 months prior to screening; or
    3. Subject treated with ERT since at least 12 months at the time of the screening visit, and agreeing to stop ERT for approximately 8 months.
  6. A woman of is eligible only under certain conditions, e.g. taking measures.
  7. Subjects with moderate or severe neuropathic pain during the screening period.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant, planning to be become pregnant, or lactating subject.
  2. Severe renal insufficiency ( \< 30 mL/min/1.73 m2) at screening.
  3. Subject on regular dialysis for the treatment of chronic kidney disease.
  4. Known and documented , stroke, unstable angina, or myocardial infarction within 6 months prior to screening.
  5. unstable cardiac disease (e.g. uncontrolled symptomatic arrhythmia, congestive heart failure class III or IV).
  6. Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
118 participants (actual)

Study arms

  • Experimental
    Lucerastat

    Drug: Lucerastat

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Hard gelatin capsules containing 250 mg of lucerastat and inactive excipients; 1000 mg (4 capsules) twice daily (b.i.d.); dose adjusted for renal function.

  • DrugPlacebo

    Placebo capsules are identical in appearance to the lucerastat capsules, and contain inactive excipients; 4 capsules b.i.d.; dose adjusted for renal function.

06

What researchers measure

Primary outcomes

  1. Neuropathic Pain Monthly Score: Change From Baseline to Month 6

    Neuropathic pain on the modified BPI-SF3: subjects rated their neuropathic pain intensity ("neuropathic pain at its worst in the last 24 hours") on an 11-point scale, from 0 (no neuropathic pain) to 10 (worst imaginable neuropathic pain).

    Time frame: From baseline to Month 6 (duration: 6 months)

Secondary outcomes

  1. Plasma Globotriaosylceramide (Gb3; in ng/ml): Change From Baseline to Month 6

    Time frame: From baseline to Month 6 (duration: 6 months)

  2. Abdominal Pain Monthly Score: Change From Baseline to Month 6

    Abdominal pain on the 11-point Numerical Rating Scale (NRS-11): subjects rated their abdominal pain intensity ("abdominal pain at its worst in the last 24 hours") on an 11-point scale, from 0 (no pain) to 10 (worst imaginable pain).

    Time frame: From baseline to Month 6 (duration: 6 months)

  3. Number of Days With Diarrhea: Change From Baseline to Month 6

    A subject was considered to have diarrhea on a specific day if at least one stool of a Bristol Stool Scale (BSS) consistency Type 6 or 7 was reported. The number of days with diarrhea at baseline and Month 6 was the number of days with diarrhea over the 4 weeks prior to the randomization visit or the Month 6 visit, respectively, adjusted for the number of days with data available.

    Time frame: From baseline to Month 6 (duration: 6 months)

07

Results

Posted Aug 9, 2024

Participant flow

The study was conducted at 49 sites in 14 countries, including North America (USA, CAN), Europe (Austria, Belgium, Germany, Ireland, Italy, Netherlands, Norway, Poland, Spain, Switzerland, UK), and Australia.

Participant flow — Overall Study
MilestoneLucerastatPlacebo
Started8038
Treated8037
Completed7534
Not completed54
Withdrew: Randomized but not treated01
Withdrew: Adverse event22
Withdrew: Withdrawal by subject30
Withdrew: Lost to follow-up01

Outcome measures

PrimaryNeuropathic Pain Monthly Score: Change From Baseline to Month 6

Neuropathic pain on the modified BPI-SF3: subjects rated their neuropathic pain intensity ("neuropathic pain at its worst in the last 24 hours") on an 11-point scale, from 0 (no neuropathic pain) to 10 (worst imaginable neuropathic pain).

Time frame:
From baseline to Month 6 (duration: 6 months)
Reported as:
Least squares mean · score on a scale
Neuropathic Pain Monthly Score: Change From Baseline to Month 6
score on a scaleLucerastatPlacebo
Neuropathic Pain Monthly Score: Change From Baseline to Month 6-1.64 (-2.11 to -1.16)-2.05 (-2.73 to -1.37)
Statistical analysis
  • Lucerastat vs Placebo · ANCOVA · p = 0.3189 · Ls mean difference vs. placebo: 0.42 · 95% CI -0.4 to 1.23
SecondaryPlasma Globotriaosylceramide (Gb3; in ng/ml): Change From Baseline to Month 6
Time frame:
From baseline to Month 6 (duration: 6 months)
Reported as:
Least squares mean · ng/ml
Plasma Globotriaosylceramide (Gb3; in ng/ml): Change From Baseline to Month 6
ng/mlLucerastatPlacebo
Plasma Globotriaosylceramide (Gb3; in ng/ml): Change From Baseline to Month 6-672.68 (-798.91 to -546.46)200.84 (14.29 to 387.40)
Statistical analysis
  • Lucerastat vs Placebo · ANCOVA · p = <0.0001 · Ls mean difference vs. placebo: -873.53 · 95% CI -1097.53 to -649.53
SecondaryAbdominal Pain Monthly Score: Change From Baseline to Month 6

Abdominal pain on the 11-point Numerical Rating Scale (NRS-11): subjects rated their abdominal pain intensity ("abdominal pain at its worst in the last 24 hours") on an 11-point scale, from 0 (no pain) to 10 (worst imaginable pain).

Time frame:
From baseline to Month 6 (duration: 6 months)
Reported as:
Least squares mean · score on a scale
Abdominal Pain Monthly Score: Change From Baseline to Month 6
score on a scaleLucerastatPlacebo
Abdominal Pain Monthly Score: Change From Baseline to Month 6-1.37 (-1.86 to -0.87)-1.68 (-2.38 to -0.98)
Statistical analysis
  • Lucerastat vs Placebo · ANCOVA · p = 0.4676 · Ls mean difference vs. placebo: 0.31 · 95% CI -0.53 to 1.16
SecondaryNumber of Days With Diarrhea: Change From Baseline to Month 6

A subject was considered to have diarrhea on a specific day if at least one stool of a Bristol Stool Scale (BSS) consistency Type 6 or 7 was reported. The number of days with diarrhea at baseline and Month 6 was the number of days with diarrhea over the 4 weeks prior to the randomization visit or the Month 6 visit, respectively, adjusted for the number of days with data available.

Time frame:
From baseline to Month 6 (duration: 6 months)
Reported as:
Mean · Number of days within 4 weeks
Number of Days With Diarrhea: Change From Baseline to Month 6
Number of days within 4 weeksLucerastatPlacebo
Number of Days With Diarrhea: Change From Baseline to Month 6-3.45 ± 4.96-3.95 ± 9.29
Statistical analysis
  • Lucerastat vs Placebo · ANCOVA · p = 0.8986 · Win ratio: 1.00 · 95% CI 0.57 to 1.89

Adverse events

Collected over Treatment-emergent adverse events from the 6-month treatment period are reported. Adverse events were considered treatment-emergent if the onset date was between the first intake of study treatment up to 30 days after the end of study treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lucerastat0/80 (0%)5/80 (6.3%)46/80 (57.5%)
Placebo0/37 (0%)1/37 (2.7%)21/37 (56.8%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventLucerastatPlacebo
Tooth abscessInfections and infestations0/801/37
Ventricular tachycardiaCardiac disorders1/800/37
Vertigo positionalEar and labyrinth disorders1/800/37
Drug withdrawal syndromeGeneral disorders1/800/37
Hepatitis viralInfections and infestations1/800/37
Localised infectionInfections and infestations1/800/37
Septic encephalopathyInfections and infestations1/800/37
Streptococcal bacteraemiaInfections and infestations1/800/37
Ischaemic strokeNervous system disorders1/800/37
Pleural effusionRespiratory, thoracic and mediastinal disorders1/800/37
Most frequent other events
Showing 10 of 21
Most frequent other events
EventLucerastatPlacebo
FatigueGeneral disorders3/806/37
NauseaGastrointestinal disorders11/801/37
NasopharyngitisInfections and infestations8/805/37
DiarrhoeaGastrointestinal disorders9/801/37
HeadacheNervous system disorders9/804/37
Abdominal distensionGastrointestinal disorders4/804/37
Glomerular filtration rate decreasedInvestigations0/804/37
FlatulenceGastrointestinal disorders7/801/37
NeuralgiaNervous system disorders6/803/37
VomitingGastrointestinal disorders6/800/37

Baseline characteristics

Age, Continuous
Age, Continuous(years)LucerastatPlaceboTotal
Median38 (18 to 74)39 (18 to 65)39 (18 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)LucerastatPlaceboTotal
Female432063
Male371855
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LucerastatPlaceboTotal
American Indian or Alaska Native000
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American000
White7637113
More than one race000
Unknown or Not Reported202
Region of Enrollment
Region of Enrollment(participants)LucerastatPlaceboTotal
United States26632
United Kingdom8311
Switzerland011
Spain7613
Canada10515
Netherlands123
Austria011
Belgium314
Norway112
Poland9413
Australia549
Germany10414
Neuropathic pain monthly score at baseline
Neuropathic pain monthly score at baseline(units on a scale)LucerastatPlaceboTotal
Mean6.26 ± 1.546.11 ± 1.396.21 ± 1.49
08

Study locations

49 sites
  • University of Alabama at Birmingham - Nephrology Research Clinic
    Birmingham, Alabama 35233, United States
  • University of California Irvine
    Irvine, California 92696, United States
  • UCSF Benioff Children's Hospital Oakland
    Oakland, California 94609, United States
  • University of Florida College of Medicine - Division of Nephrology, Hypertension & Renal Transplantation
    Gainesville, Florida 32610, United States
  • Emory University School of Medicine; Department of Human Genetics
    Atlanta, Georgia 30322, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Iowa Stead Family Children's Hospital - Division of Medical Genetics
    Iowa City, Iowa 52242, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Infusion Associates
    Grand Rapids, Michigan 49525, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Pittsburgh (UPMC)
    Pittsburgh, Pennsylvania 15224, United States
  • Greenwood Genetic Center
    Greenville, South Carolina 29605, United States
  • Research Baylor Institute of Metabolic Disease
    Dallas, Texas 75226, United States
  • University of Utah - Division of Medical Genetics
    Salt Lake City, Utah 84113, United States
  • Lysosomal and Rare Disorders Research and Treatment Center
    Fairfax, Virginia 22030, United States
  • Royal Melbourne Hospital - Department of Nephrology
    Parkville, 3050, Australia
  • Royal Perth Hospital, Department of Nephrology
    Perth, 6000, Australia
  • Allgemeines Krankenhaus der Stadt Wien - Universitätsklinik für Innere Medizin III - Klinische Abteilung für Nephrologie und Dialyse
    Vienna, 1090, Austria
  • University Hospital Ghent
    Ghent, 9000, Belgium
  • University Hospital Leuven
    Leuven, 3000, Belgium
  • London Health Sciences Centre - Victoria Hospital
    London, Ontario N6A 5W9, Canada
  • M.A.G.I.C Clinic Ltd
    Calgary, T2M 0L6, Canada
  • Queen Elizabeth II Health Sciences Center - Halifax Infirmary - Division of Nephrology
    Halifax, B3H 3A7, Canada
  • Research Center, Hôpital Du Sacré-Coeur de Montréal
    Montréal, H4J 1C5, Canada
  • Vancouver Hospital & Health Sciences - Vancouver General Hospital
    Vancouver, V5Z 1M9, Canada
  • Health Sciences Center Winnipeg
    Winnipeg, R3A 1S1, Canada
  • Charite Campus Virchow-Klinikum - Nephrologie und Internistische Intensivmedizin
    Berlin, 13353, Germany
  • SphinCS GmbH
    Hochheim, 65239, Germany
  • Fachinternistische Gemeinschaftspraxis Markgräferland
    Mühlheim, 79379, Germany
  • Medizinische Klinik und Poliklinik I der Universität - Schwerpunkt Nephrologie
    Würzburg, 97080, Germany
  • Hosp Alma Mater Studiorum
    Dublin, DD7 R2WY, Ireland
  • ASST Monza, Hospital San Gerardo, Nephrology
    Monza, 20900, Italy
  • University of Naples Federico II (Nephrology)
    Naples, 80131, Italy
  • Hospital Academisch Medisch Centrum - Department of Internal Medicine Div. Endrocrinology and Metabolism
    Amsterdam, 22660, Netherlands
  • Haukeland University Hospital Helse Bergen HF
    Bergen, 5021, Norway
  • University Hospital in Cracow - Dep. of of Allergies and Immunology
    Krakow, 31-066, Poland
  • Cardinal Wyszynski Institute of Cardiology
    Warsaw, 04-628, Poland
  • Department of Pediatric Nutrition and Metabolic Diseases; The Children's Memorial Health Institute
    Warsaw, 04-730, Poland
  • Hospital Universitari Vall d'Hebrón
    Barcelona, 08035, Spain
  • Hospital Universitari de Bellvitge; Hospitalet de Llobregat
    Barcelona, 08907, Spain
  • Hospital Universitario Ramon y Cajal. Servicio de Medicina Interna
    Madrid, 28034, Spain
  • Hospital Quironsalud Zaragoza
    Zaragoza, 50012, Spain
  • Universität Zürich Psychiatrische Universitätsklinik
    Zurich, 8032, Switzerland
  • University Hospital Birmingham NHS Foundation Trust - Center for Rare Diseases
    Birmingham, B15 2WB, United Kingdom
  • The Royal Free Hospital, Department of Haematology Royal Free London NHS Foundation Trust
    London, NW3 2QG, United Kingdom
  • National Hospital for Neurology and Neurosurgery
    London, WC1N3BG, United Kingdom
  • Salford Royal (Hope) Hospital
    Salford, M6 8HD, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Aug 2021, 37 months.

Results were first posted in Aug 2024, 2 years 11 months after primary completion. A results delay was requested in Aug 2022.

Of 22 phase 3 interventional studies under Fabry Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 64. This study's 37 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2018
First posted
Feb 7, 2018
StartActual
Jun 21, 2018
Primary completionActual
Aug 17, 2021
CompletionActual
Sep 2, 2021
Results delay requested
Aug 2, 2022
Results first posted
Aug 9, 2024
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03425539
Responsible party
Sponsor
First posted
Feb 7, 2018
Start date
Jun 21, 2018
Primary completion
Aug 17, 2021
Completion
Sep 2, 2021
Results posted
Aug 9, 2024
Last update
Aug 9, 2024

Study contacts

Clinical Trials
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Migalastat

Start the discussion